NNT Color recommendation	Yellow (Unclear if benefits)
Summary Heading	Higher‐dose anticoagulation did not improve survival and increased bleeding, but decreased venous thromboembolism
Benefits in NNT	No benefit in all‐cause mortality 1 in 45 were helped (reduced venous thromboembolism)
Benefits in Percentages (absolute risk reduction)	No benefit in all‐cause mortality, stroke, myocardial infarction, systemic arterial embolism 2.2% lower risk of venous thromboembolism
Harms in NNT (NNH)	1 in 101 were harmed (increased risk of major bleeding) 1 in 18 were harmed (increased risk of any bleeding)
Harms in Percentages	1% increased risk of major bleeding 5.3% increased risk of any bleeding
Efficacy Endpoints	All‐cause mortality, venous thromboembolism, stroke, myocardial infarction, systemic arterial embolism
Harm Endpoints	Major bleeding, any bleeding
Who was in the studies	7 trials of 5,145 hospitalized patients with COVID‐19